Assessment of chimerism and immunomodulation to prevent post-transplantation relapse in childhood acute myeloblastic leukemia: is it the right approach?

Affiliation auteurs!!!! Error affiliation !!!!
TitreAssessment of chimerism and immunomodulation to prevent post-transplantation relapse in childhood acute myeloblastic leukemia: is it the right approach?
Type de publicationJournal Article
Year of Publication2020
AuteursCousin E, Oger E, Dalle J-H, Bertrand Y, Pertuisel S, Pochon C, Galambrun C, Simon P, Bruno B, Paillard C, Schneider P, Rohrlich P, De La Tour RPeffault, Freycon C, Eliaou J-F, Semana G, Jonveaux P, Drunat S, Bordigoni P, Gandemer V
JournalPEDIATRIC HEMATOLOGY AND ONCOLOGY
Volume37
Pagination259-268
Date PublishedAPR 2
Type of ArticleArticle
ISSN0888-0018
Mots-clésacute myeloid leukemia, chimerism, donor lymphocyte infusions, Immunotherapy, relapse of acute myeloblastic leukemia, stem cell transplantation
Résumé

Relapse of acute myeloblastic leukemia (AML) after first allogenic hematopoietic stem-cell transplantation (allo-HSCT) is a fatal complication. Sixty-five children transplanted for AML were included in a prospective national study from June 2005 to July 2008 to explore the feasibility of preemptive immune modulation based on the monitoring of blood chimerism. Relapse occurred in 23 patients (35%). The median time between the last complete chimerism and relapse was 13.5 days (2-138). Prompt discontinuation of cyclosporin and the administration of donor lymphocyte infusions (DLIs) based on chimerism monitoring failed as a preemptive tool, either for detecting relapse or certifying long-term remission.
DOI10.1080/08880018.2020.1717697